SinoMab Bioscience Ltd. (HK:3681)
:3681
Want to see HK:3681 full AI Analyst Report?
3681 Stock Chart & Stats
HK$1.39
-HK$0.01(-1.00%)
At close: 4:00 PM EST
HK$1.39
-HK$0.01(-1.00%)
Day’s Range― - ―
52-Week RangeHK$1.16 - HK$3.76
Previous CloseN/A
Volume24.00K
Average Volume (3M)6.26M
Market Cap
HK$1.65B
Enterprise ValueHK$1.23B
Total Cash (Recent Filing)HK$382.40M
Total Debt (Recent Filing)HK$338.64M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding1,386,638,300
10 Day Avg. Volume8,278,616
30 Day Avg. Volume6,255,789
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)2.91
Price to Sales (P/S)0.00
P/FCF Ratio-15.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)HK$8.71M
Bulls Say, Bears Say
Bulls Say
Improved LeverageMaterial deleveraging in 2025 reduces immediate refinancing pressure and modestly extends strategic optionality. A stronger balance mix lowers bankruptcy risk, improves access to capital markets and partnership attractiveness, helping fund clinical programs over the medium term.
Narrowing LossesA contraction in net losses indicates progress on cost control or development efficiencies, improving the company’s cash runway trajectory. Sustained narrowing could make future funding needs smaller and increase the feasibility of advancing lead programs toward value-inflection points.
Therapeutic FocusConcentrated expertise in monoclonal antibodies for immunology/inflammatory diseases aligns with persistent clinical demand and established commercial channels. This domain knowledge supports durable competitive positioning and makes strategic partnerships or licensing plausible long-term monetization paths.
Bears Say
Zero RevenueA collapse to zero reported revenue signals no meaningful product commercialization and leaves the company reliant on external financing or one-off nonrecurring items. That structural lack of operating income raises execution risk and challenges sustainable funding over multiple quarters.
Persistent Cash BurnRepeated negative operating and free cash flow shows the business cannot self-fund development and must access capital markets. Ongoing burn increases dilution and financing risk, and if market conditions or partners tighten, program continuity and timelines could be materially disrupted.
Consistent LossesSustained operating losses drive negative returns on shareholder capital and erode equity value over time. Persistent unprofitability limits reinvestment ability, increases dependency on external funding, and raises the risk that programs may be delayed or cut if capital access weakens.
SinoMab Bioscience Ltd. News
3681 FAQ
What was SinoMab Bioscience Ltd.’s price range in the past 12 months?
SinoMab Bioscience Ltd. lowest stock price was HK$1.16 and its highest was HK$3.76 in the past 12 months.
What is SinoMab Bioscience Ltd.’s market cap?
SinoMab Bioscience Ltd.’s market cap is HK$1.65B.
When is SinoMab Bioscience Ltd.’s upcoming earnings report date?
SinoMab Bioscience Ltd.’s upcoming earnings report date is Aug 24, 2026 which is in 82 days.
How were SinoMab Bioscience Ltd.’s earnings last quarter?
SinoMab Bioscience Ltd. released its earnings results on Mar 23, 2026. The company reported -HK$0.044 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.044.
Is SinoMab Bioscience Ltd. overvalued?
According to Wall Street analysts SinoMab Bioscience Ltd.’s price is currently Overvalued.
Does SinoMab Bioscience Ltd. pay dividends?
SinoMab Bioscience Ltd. does not currently pay dividends.
What is SinoMab Bioscience Ltd.’s EPS estimate?
SinoMab Bioscience Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SinoMab Bioscience Ltd. have?
SinoMab Bioscience Ltd. has 1,386,638,300 shares outstanding.
What happened to SinoMab Bioscience Ltd.’s price movement after its last earnings report?
SinoMab Bioscience Ltd. reported an EPS of -HK$0.044 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.183%.
Which hedge fund is a major shareholder of SinoMab Bioscience Ltd.?
Currently, no hedge funds are holding shares in HK:3681
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SinoMab Bioscience Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
44.64%
12-Months-Change
Fundamentals
Return on Equity
-27.70%
Trailing 12-Months
Asset Growth
26.20%
Trailing 12-Months
Company Description
SinoMab Bioscience Ltd.
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, as well as in phase 1 clinical trial to treat multiple sclerosis, SLE, and NMOSD. Its products under the preclinical stage comprise SM17 for the treatment of asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06 to treat RA, SLE, NMOSD, and SS; SM09 for the treatment of NHL and RA; and TNF2 for the treatment of autoimmune diseases. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Technical Analysis
Genor Biopharma Holdings Limited
―
Alphamab Oncology
―
Mabpharm Limited
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―